1.
Leuk Res Rep
; 17: 100291, 2022.
Article
in English
| MEDLINE | ID: covidwho-1670861
ABSTRACT
We report a case of FLT3-mutated AML with t(6;9) in which induction chemotherapy with DA and midostaurin failed to achieve complete cytogenetic or molecular remission. Due to the COVID-19 pandemic and co-existing cellulitis, monotherapy with the selective FLT3-inhibitor gilteritinib was used as an alternative consolidation treatment option rather than further intensive chemotherapy. Gilteritinib was able to achieve complete molecular and cytogenetic remission despite the additional cytogenetic abnormality. This case provides supporting evidence for the use of single agent gilteritinib in high-risk primary refractory FLT3-mutated AML with t(6;9) prior to transplantation.
2.
Br J Haematol
; 190(4): e208-e210, 2020 08.
Article
in English
| MEDLINE | ID: covidwho-998784
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , COVID-19 Drug Treatment , COVID-19 , Leukemia, Myeloid, Acute , Mutation , Nuclear Proteins/genetics , SARS-CoV-2 , Adult , COVID-19/blood , COVID-19/genetics , Cytarabine/administration & dosage , Daunorubicin/administration & dosage , Gemtuzumab/administration & dosage , Humans , Leukemia, Myeloid, Acute/blood , Leukemia, Myeloid, Acute/drug therapy , Leukemia, Myeloid, Acute/genetics , Male , Neoplasm, Residual , Nucleophosmin
3.
Br J Haematol
; 190(2): e80-e83, 2020 07.
Article
in English
| MEDLINE | ID: covidwho-625516
4.
Br J Haematol
; 190(4): e189-e191, 2020 08.
Article
in English
| MEDLINE | ID: covidwho-614297